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How does the key, a Rho family GTPase, open the
lock? Previous structural studies have shown that Rho
interacts with both the GBD and DID domains (Li and
Higgs, 2005; Rose et al., 2005). It has also been shown
that the DAD-interacting DID domain is sufficient for
the autoinhibition of Diaphanous activities (Li and Higgs,
2005). However, through the superposition of the previ-
ously determined RhoA/GBD-DID-DD complex struc-
ture with that of the DAD/DID complex, Eck and co-
workers (Nezami et al., 2006) show that only one RhoA
residue may collide with the DAD domain. While this
potential collision may contribute to the competition
between RhoA and DAD, a more important switching
mechanism may rely on the GBD domain. In the absence
of a Rho-GTPase, the GBD region is largely unstructured
(Otomo et al., 2005a; Nezami et al., 2006). In the pres-
ence of RhoA, the GBD becomes well ordered and has
a rigid configuration relative to the neighboring DID do-
main, which occludes the binding of DAD on the DID do-
main (Nezami et al., 2006). The authors note that this ap-
pears to be a general scheme for many GTPases to exert
their regulatory role by binding to the regulatory domain
(the DID domain in this case) as well as a neighboring re-
gion (the ‘‘access point’’ as termed by Otomo et al.
[2005a], the GBD domain in this case).
How does this DID-DAD lock encage or block the
function of the FH2 domain in full-length DRFs? Previ-
ous studies indicated that, in addition to the DAD do-
main, the DID domain may also interact directly with
the FH2 domain (Li and Higgs, 2005). Calorimetric anal-
ysis reported by Eck and coworkers shows that the
presence of the FH2 domain does not dramatically en-
hance the binding of its C-terminal flanking DAD domain
to the DID domain (Nezami et al., 2006). However, the
direct interaction between DID and FH2 domains still
cannot be ruled out in the intramolecular scenario. An
important factor adding to the complexity of DRFs auto-
inibition is the dimerization or oligomerization of DRF
proteins. Both the FH2 and DD domains of DRFs pro-
mote dimerization (Higgs, 2005; Zigmond, 2004). It re-
mains unclear if the so-called ‘‘intramolecular’’ interac-
tion is indeed formed within a single DRF molecule, or
formed between DID and DAD domains of DRF homo-
dimer/homo-oligomers. Our complete understanding
of the autoinhibition mechanism will have to wait for
future structural and biochemical studies of the full-
length DRFs.
In addition, in vitro studies showed that mDia1 autoin-
hibition is not fully relieved by RhoA (Li and Higgs, 2005).
It is thus possible that DRFs can be regulated by factors
other than GTPases. Nevertheless, with the addition of
this current work, the molecular mechanisms underlying
formin regulation have been largely unraveled in a
domain-by-domain approach. The next goal for the field
is the structure of the full-length DRF or DRF fragments
that contain all regulatory, dimerization, and functional
(FH2) domains.
Wenqing Xu
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In this issue of Structure, Chrencik et al. (2006) report
a structural and thermodynamic analysis of EphB4 in
complex with an antagonistic peptide; the insight
into Eph-ephrin interaction suggests determinants
for Eph receptor specificity. These findings will con-
tribute to the development of EphB4 antagonists for
therapeutic applications.
The Eph receptors comprise the largest family of recep-
tor tyrosine kinases (InterPro database, http://www.ebi.ac.uk/interpro, entry IPR001426); they have extracellular
and cytoplasmic domains flanking a median transmem-
brane region (InterPro IPR001090). The receptors are
divided into two classes based on the properties of
the corresponding ephrin ligands. While ephrin-A li-
gands are attached to the extracellular side of the cell
membrane via a GPI anchor, ephrin-B ligands have a trans-
membrane region and both extracellular and cytoplas-
mic domains (Interpro, IPR001799). In a cell-contact-
dependent interaction, signaling is propagated in both
the receptor-expressing and the ligand-expressing cells,
a property particular to Eph signaling. The Eph recep-
tors and ligands were originally identified as neuronal
pathfinding molecules. Genetic ablation experiments
in mice have demonstrated that Eph signaling has
Structure
170essential functions in numerous biological processes
both during embryonic development and in adult homeo-
stasis (for a review, see Brantley-Sieders and Chen
[2004] and references therein).
Ephrin-A ligands bind promiscuously to EphA recep-
tors, but do not display high affinity for the EphB recep-
tors. Similarly, ephrin-B ligands bind to EphB receptors
and not to the receptors of the EphA class. There are no-
table exceptions to this subclass discrimination, for ex-
ample EphA4 can bind ligands from both subclasses
(Takemoto et al., 2002), and EphB2 can bind both
ephrin-B ligands and also ephrin-A5 (Himanen et al.,
2004). The promiscuity in binding of the ephrins to their
cognate Eph receptors makes the identification of selec-
tive antagonists for these receptors a challenging task.
Over the last decade in an outstanding sequence of
publications, Himanen and coworkers have described
the structure of the ligand binding domain of EphB2 re-
ceptor, its complex with ephrin-B2 (Himanen et al.,
2001), and more recently its complex with ephrin-A5
(Himanen et al., 2004). This work has revealed the mo-
lecular architecture of the ligand binding domain of
Eph receptors and ephrins, and set the foundation for
understanding the molecular profile of Eph receptor-
ligand interactions.
In new work, Kuhn and coworkers present a structural
and thermodynamic analysis of the interaction between
EphB4 and a peptide antagonist (Chrencik et al., 2006).
EphB4 and ephrin-B2 play essential roles during vascu-
lar development; mice deficient in either EphB4 or
ephrin B2 die due to vascular defects (Adams et al.,
1999). Stimulation of ephrin-B2 signaling by EphB4 has
been shown to promote tumor growth in vivo (Noren
et al., 2004), and EphB4 expression is upregulated in
several cancers. Accumulating evidence on the precise
roles of EphB4-ephrin-B2 signaling during tumor angio-
genesis and pathological forms of angiogenesis sug-
gests the pair as promising drug target candidates.
EphB4 is highly selective for its interaction with ligands
(unlike EphB2, which is activated by many ephrins) and
is mainly activated only by ephrin-B2. Consequently,
these results represent an important step in the design
of specific antagonists of EphB4 signaling.
The structure of the selective EphB4 (Chrencik et al.,
2006) is overall very similar to the promiscuous EphB2
(Himanen et al., 2001, 2004); however, important differ-
ences occur. The high resolution of the structure en-
ables a detailed analysis of interactions between
EphB4 and the specific antagonistic TNYL-RAW peptide
(Chrencik et al., 2006). Positioning of the Eph loops re-
sponsible for interaction with ephrins is significantly dif-
ferent in the new EphB4 structure as compared to both
structures of EphB2 bound to ephrins (Himanen et al.,
2001, 2004). The interactions of the TNYL-RAW peptide
with EphB4 as observed in the crystal structure are ver-
ified by an excellent, detailed thermodynamic analysis
based on isothermal titration calorimetry experiments.
The measured DG for the EphB4-TNYL-RAW peptide
interaction is 29.8 kcal mol21 (Chrencik et al., 2006), in
very good agreement with the solvation free energy
gain (DiG) calculated from the structure (212.1 kcal
mol21; http://www.ebi.ac.uk/msd-srv/prot_int/pistart.
html). Although this DG is similar to that measured for
the binding of ephrin-B2 to EphB4 (210.2 kcal mol21)and the respective Kds are close (71 6 14 and 40 6
20 nM, respectively), the interaction of EphB4 with the
antagonistic peptide is dominated by a favorable en-
thalpic contribution (214.7 kcal mol21), while the inter-
action with the ephrin-B2 ligand is driven by a favorable
entropy change of 13.4 kcal mol21 (Chrencik et al.,
2006). For ephrin-B2 and EphB2, complex formation re-
sults in a calculated DiG between 210.1 and 212.9 kcal
mol21; upon complex formation between ephrin-A5
and EphB2 the calculated DiG is about 26.1 kcal mol21
(calculated from the structures by Himanen et al.
[2001, 2004]). These observations demonstrate that the
affinity of ephrin-B2 to EphB4 is similar to it’s affinity
to EphB2, while ephrin-A5 binds significantly weaker
to EphB2.
Kuhn and coworkers also comment on the possible
further dimerization of the Eph4B4 and ephrin-B2 com-
plex, a concept introduced previously (Himanen et al.,
2001) based on the EphB2 structure in complex with
ephrin-B2; there, the receptor-ligand complex forms
a higher-order dimer, where each ligand interacts with
both receptors and vise versa (forming practically a tet-
ramer). This ‘‘tetramerization’’ results in a favorable DiG
of between24.1 and26.3 kcal mol21. However, solution
studies with biophysical methods should clarify further
the relevance of the tetramerisation observed in the
EphB2-ephrin-B2 crystal structure and can also clarify
if tetramerisation holds true for the EphB4-ephrin-B2
complex.
Undoubtedly the ability to manipulate EphB4-ephrin-
B2 binding will be very important in gaining insight into
the roles of this signaling system in angiogenesis and
tumor progression. It will also facilitate the molecular
characterization of commonalities between vascular de-
velopment, axon guidance, and tissue patterning mech-
anisms. Identification of more selective antagonists for
EphB4 holds the potential to enable inhibition of tumor
angiogenesis and aberrant angiogenesis in disease
states.
Given the complexity of mechanisms operating during
tumor progression, though, caution is required when de-
signing therapeutic strategies. A relevant example is the
case of EphB2, which has been proposed as a target
for antibody-based cancer therapy, based on its upreg-
ulated expression in colorectal cancer (Mao et al.,
2004). However, it was shown that loss of EphB2 expres-
sion (and indeed coordinated silencing of all EphB re-
ceptors including EphB4) represents a critical step in
colorectal cancer progression (Batlle et al., 2005); thus,
silencing Eph signaling may promote rather than inhibit
tumorigenesis. These studies underscore the necessity
for comprehensive and detailed validation of potential
drug targets.
The findings presented by Chrencik et al. (2006) on
the EphB4-ephrin-B2 interaction may also have a
broader scope of applications, including the field of
virus outbreak management. Ephrin-B2 was recently
identified as the entry receptor for the deadly Nipah virus
(NiV), which attacks endothelial cells and neurons and
causes fatal encephalitis in the majority of infected pa-
tients (Negrete et al., 2005). It was suggested that the
identification of ephrin-B2 as the NiV receptor may
facilitate screening of antagonists to block NiV entry.
The detailed structural characterization of ephrin-B2
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171antagonists binding to EphB4 will also contribute to
these efforts.
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Decapper Comes into Focus
In this issue of Structure, Scarsdale et al. (2006) report
structures of the Xenopus X29 Nudix decapping
protein, including homodimer structures in complex
with cap nucleotides. These structures reveal insights
into the mechanism of cap substrate recognition and
predict an RNA binding path on the protein surface.
The small nucleolar RNAs (snoRNAs) are a group of non-
coding RNAs that associate with nucleolar proteins
to form small nucleolar ribonucleoprotein particles
(snoRNPs) that play well-established roles in ribosomal
RNA (rRNA) processing. Although over a hundred
snoRNPs are involved in the various rRNA modifica-
tions, only a handful are necessary for cleavage of the
45S pre-rRNAs into the three mature rRNAs. Among
these, the U8 snoRNP is essential for both 5.8S and
28S rRNA production (Peculis and Steitz, 1993). The
U8 snoRNA is transcribed by RNA polymerase II and,
like many small nuclear RNAs and snoRNAs, is subse-
quently hypermethylated at the 50 end to a m2,2,7G trime-
thylated capped RNA.
Initial gel shift analysis of the U8 snoRNA revealed
a 29 kDa polypeptide from Xenopus ovary extract,
termed X29, that specifically bound the RNA (Tomasevic
and Peculis, 1999). The novel protein was identified and
found to contain an evolutionarily conserved Nudix (nu-
cleotide diphosphatase linked to moiety X) motif con-
sisting of an w23 amino acid consensus sequence,
GX5EX7REUXEEXGU, where X denotes any residue
and U represents Ile, Leu, or Val (Mildvan et al., 2005).
Similar to Dcp2, a Nudix protein which hydrolyzes cap-
ped messenger RNA to release m7GDP (known as the
decapping reaction), X29 was also shown to possess de-
capping activity and to decap U8 snoRNA preferentially,
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phate (Ghosh et al., 2004). In this issue, Scarsdale et al.
(2006) provide structural insight into the substrate bind-
ing of the X29 Nudix decapping protein to a cap moiety.
Decapping enzymes play well-characterized roles in
mRNA degradation. The crystal structures of the three
known catalytically active decapping enzymes have
now been solved: the scavenger decapping protein
DcpS, the mRNA decapping protein Dcp2, and the nu-
cleolar decapping protein X29 (Gu et al., 2004; Scarsdale
et al., 2006; She et al., 2006). DcpS is distinct in that it
harbors a histidine triad decapping motif, while X29
and Dcp2 are both Nudix-containing proteins. Scarsdale
et al. (2006) report a series of crystal structures for the
homodimeric X29 apo protein and the metal- and nucle-
otide bound X29 holo-protein. The structures confirm
the presence of the characteristic a/b/a sandwich Nudix
fold structure within X29. A comparison of the structural
alignment of X29 with that of the recently reported
amino-terminal fragment of the Schizosaccharomyces
pombeDcp2 monomer reveals conservation in the over-
all Nudix fold structure (Figure 1A). As expected, the
core a helix of the Nudix motif is highly conserved, par-
ticularly in the identical positioning of the critical gluta-
mates previously shown to be essential for X29 and
Dcp2 decapping activities (Coller and Parker, 2004).
The X29 Nudix protein is surprisingly unique among
cap binding proteins structurally characterized thus
far. Previous structural studies have broadly illustrated
that cap substrates insert into a binding pocket that pro-
vides general interactions and specific contacts to the
m7G nucleobase (Marcotrigiano et al., 1997). Common
features of proteins that form a complex with cap analog
are pi-pi stacking via two aromatic residues sandwich-
ing the m7G base, and hydrogen bonding between the
m7G base and the vicinal side chain of an acidic amino
acid, as initially revealed for the eIF4E cap binding
protein (Marcotrigiano et al., 1997). For example, in
the crystal structure of cap bound DcpS, a plethora of
van der Waals, general stacking, and hydrogen bond
